1. Home
  2. PLRX vs WLDN Comparison

PLRX vs WLDN Comparison

Compare PLRX & WLDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLRX
  • WLDN
  • Stock Information
  • Founded
  • PLRX 2015
  • WLDN 1964
  • Country
  • PLRX United States
  • WLDN United States
  • Employees
  • PLRX N/A
  • WLDN N/A
  • Industry
  • PLRX Biotechnology: Pharmaceutical Preparations
  • WLDN Military/Government/Technical
  • Sector
  • PLRX Health Care
  • WLDN Consumer Discretionary
  • Exchange
  • PLRX Nasdaq
  • WLDN Nasdaq
  • Market Cap
  • PLRX 641.5M
  • WLDN 581.0M
  • IPO Year
  • PLRX 2020
  • WLDN 2006
  • Fundamental
  • Price
  • PLRX $11.60
  • WLDN $37.99
  • Analyst Decision
  • PLRX Strong Buy
  • WLDN Strong Buy
  • Analyst Count
  • PLRX 7
  • WLDN 3
  • Target Price
  • PLRX $40.50
  • WLDN $44.33
  • AVG Volume (30 Days)
  • PLRX 544.2K
  • WLDN 122.5K
  • Earning Date
  • PLRX 02-26-2025
  • WLDN 03-06-2025
  • Dividend Yield
  • PLRX N/A
  • WLDN N/A
  • EPS Growth
  • PLRX N/A
  • WLDN 802.09
  • EPS
  • PLRX N/A
  • WLDN 1.63
  • Revenue
  • PLRX N/A
  • WLDN $577,414,000.00
  • Revenue This Year
  • PLRX N/A
  • WLDN N/A
  • Revenue Next Year
  • PLRX N/A
  • WLDN $7.28
  • P/E Ratio
  • PLRX N/A
  • WLDN $23.16
  • Revenue Growth
  • PLRX N/A
  • WLDN 23.47
  • 52 Week Low
  • PLRX $10.22
  • WLDN $18.15
  • 52 Week High
  • PLRX $18.92
  • WLDN $50.00
  • Technical
  • Relative Strength Index (RSI)
  • PLRX 39.38
  • WLDN 44.88
  • Support Level
  • PLRX $11.02
  • WLDN $34.73
  • Resistance Level
  • PLRX $12.70
  • WLDN $39.09
  • Average True Range (ATR)
  • PLRX 0.83
  • WLDN 1.22
  • MACD
  • PLRX -0.16
  • WLDN 0.13
  • Stochastic Oscillator
  • PLRX 17.93
  • WLDN 72.44

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

About WLDN Willdan Group Inc.

Willdan Group Inc is a provider of professional technical and consulting services to utilities, private industry, and public agencies at all levels of government. It operates in the business segments of Energy and Engineering and Consulting. It generates the majority of its revenue from the Energy segment, which includes services such as audit and surveys, program design, master planning, benchmarking analysis, design engineering, construction management, performance contracting, installation, advances in software and data analytics, and other services. All of its revenue is derived from the domestic markets.

Share on Social Networks: